Prognostic impact of immune-related adverse events with nivolumab or pembrolizumab monotherapy in patients with advanced gastric cancer: A multicenter retrospective analysis

被引：0
|
作者：
Motoo, I. [1 ]
Ando, T. [1 ]
Ueda, A. [2 ]
Ogawa, K. [3 ]
Kajiura, S. [1 ]
Hirano, K. [4 ]
Okumura, T. [4 ]
Tsukada, K. [5 ]
Hara, T. [6 ]
Suzuki, N. [7 ]
Nakada, N. [8 ]
Takatori, S. [9 ]
Horikawa, N. [10 ]
Fujii, T. [4 ]
Yasuda, I. [1 ]
机构：
[1] Univ Toyama, Dept Internal Med 3, Toyama, Japan
[2] Toyama Red Cross Hosp, Dept Med Oncol, Toyama, Japan
[3] Toyama Prefectural Cent Hosp, Dept Gastroenterol, Toyama, Japan
[4] Univ Toyama, Acad Assembly, Dept Surg & Sci, Fac Med, Toyama, Japan
[5] Kouseiren Takaoka Hosp, Takaoka, Toyama, Japan
[6] Koseiren Takaoka Hosp, Dept Surg, Takaoka, Toyama, Japan
[7] Joetsu Gen Hosp, Dept Gastroenterol, Joetsu, Japan
[8] Itoigawa Sogo Hosp, Dept Internal Med, Itoigawa, Japan
[9] Saiseikai Toyama Hosp, Dept Gastroenterol, Toyama, Japan
[10] Takaoka City Hosp, Dept Surg, Takaoka, Toyama, Japan
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.04.260
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-178
引用
收藏
页码：S148 / S148
页数：1
相关论文
共 50 条
  • [21] Association Between Immune-Related Adverse Events and Clinical Efficacy in Patients with Melanoma Treated With Nivolumab: A Multicenter Retrospective Study
    Okada, Naoto
    Kawazoe, Hitoshi
    Takechi, Kenshi
    Matsudate, Yoshihiro
    Utsunomiya, Ryo
    Zamami, Yoshito
    Goda, Mitsuhiro
    Imanishi, Masaki
    Chuma, Masayuki
    Hidaka, Noriaki
    Sayama, Koji
    Kubo, Yoshiaki
    Tanaka, Akihiro
    Ishizawa, Keisuke
    CLINICAL THERAPEUTICS, 2019, 41 (01) : 59 - 67
  • [22] Immune-related adverse events to predict survival in patients with advanced non-small cell lung cancer treated with nivolumab: A multicenter analysis.
    Ricciuti, Biagio
    De Giglio, Andrea
    Brambilla, Marta
    Bassanelli, Maria
    Metro, Giulio
    Ludovini, Vienna
    Baglivo, Sara
    Chiari, Rita
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [23] Impact of Immune-Related Adverse Events on Survival in Patients with Advanced Non-Small Cell Lung Cancer Treated with Nivolumab
    Ricciuti, B.
    Genova, C.
    De Giglio, A.
    Brambilla, M.
    Bassanelli, M.
    Dal Bello, M. G.
    Baglivo, S.
    Metro, G.
    Grossi, F.
    Chiari, R.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S390 - S391
  • [24] Correlation of Immune-Related Adverse Events and Effects of Pembrolizumab Monotherapy in Patients with Non-Small Cell Lung Cancer
    Noguchi, Susumu
    Suminaga, Keiichiro
    Kaki, Takahiro
    Kawachi, Hiroaki
    Fukao, Akari
    Terashita, Satoshi
    Horikawa, Sadao
    Ikeue, Tatsuyoshi
    Sugita, Takakazu
    LUNG CANCER-TARGETS AND THERAPY, 2020, 11 : 53 - 57
  • [25] Impact of immune-related adverse events on the therapeutic efficacy of pembrolizumab in urothelial carcinoma: a multicenter retrospective study using time-dependent analysis
    Kawai, Taketo
    Taguchi, Satoru
    Nakagawa, Tohru
    Kamei, Jun
    Nakamura, Yu
    Obinata, Daisuke
    Yamaguchi, Kenya
    Kaneko, Tomoyuki
    Kakutani, Shigenori
    Tokunaga, Mayuko
    Uemura, Yukari
    Sato, Yusuke
    Enomoto, Yutaka
    Nishimatsu, Hiroaki
    Fujimura, Tetsuya
    Fukuhara, Hiroshi
    Takahashi, Satoru
    Kume, Haruki
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (02)
  • [26] Association Between the Occurrence and Spectrum of Immune-Related Adverse Events and Efficacy of Pembrolizumab in Asian Patients With Advanced Urothelial Cancer: Multicenter Retrospective Analyses and Systematic Literature Review
    Kijima, Toshiki
    Fukushima, Hiroshi
    Kusuhara, Shota
    Tanaka, Hajime
    Yoshida, Soichiro
    Yokoyama, Minato
    Ishioka, Junichiro
    Matsuoka, Yoh
    Numao, Noboru
    Sakai, Yasuyuki
    Saito, Kazutaka
    Matsubara, Nobuaki
    Yuasa, Takeshi
    Masuda, Hitoshi
    Yonese, Junji
    Kageyama, Yukio
    Fujii, Yasuhisa
    CLINICAL GENITOURINARY CANCER, 2021, 19 (03) : 208 - +
  • [27] Cutaneous immune-related adverse events are undertreated in advanced cancer patients
    Chang, M.
    Otto, T.
    Jacoby, T.
    Thompson, L.
    Reynolds, K.
    Chen, S.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2021, 141 (09) : B10 - B10
  • [28] CORRELATION BETWEEN IMMUNE-RELATED ADVERSE EVENTS SPECTRUM AND PROGNOSIS IN PATIENTS WITH ADVANCED UROTHELIAL CANCER TREATED WITH PEMBROLIZUMAB
    Tamiya, Takashi
    Kijima, Toshiki
    Tanaka, Hajime
    Yoshida, Soichiro
    Ishioka, Junichiro
    Matsuoka, Yoh
    Numao, Noboru
    Sakai, Yasuyuki
    Saito, Kazutaka
    Matsubara, Nobuaki
    Yuasa, Takeshi
    Masuda, Hithoshi
    Yonese, Junji
    Kageyama, Yukio
    Fujii, Yasuhisa
    JOURNAL OF UROLOGY, 2020, 203 : E743 - E744
  • [29] A bibliometric analysis of immune-related adverse events in cancer patients and a meta-analysis of immune-related adverse events in patients with hepatocellular carcinoma
    Wang, Bengang
    Hao, Xiangjun
    Yan, Jinshan
    Li, Xin
    Zhao, Mingfang
    Han, Tao
    JOURNAL OF TRANSLATIONAL INTERNAL MEDICINE, 2024, 12 (03) : 225 - 243
  • [30] Immune-related Adverse Events in Cancer Patients
    Pallin, Daniel J.
    Baugh, Christopher W.
    Postow, Michael A.
    Caterino, Jeffrey M.
    Erickson, Timothy B.
    Lyman, Gary H.
    ACADEMIC EMERGENCY MEDICINE, 2018, 25 (07) : 819 - 827
12345